Physician profile
Sharan Sharma
NPI 1346598166
$4,226.00
in general payments reported to CMS, 2019-2025
23 companies · $77.39 in 2025
The $77.39 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $120 · 2020: $140 · 2021: $914 · 2022: $1,033 · 2023: $872 · 2024: $1,070 · 2025: $77.39.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,920 · Education: $98.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,919.65 |
| Education | $98.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $757.43 | 2021-2025 | Opsumit, Uptravi |
| Abbott Laboratories | $580.30 | 2021-2024 | Mitraclip, Graftmaster |
| Astrazeneca Pharmaceuticals LP | $391.64 | 2020-2024 | Farxiga, Lokelma |
| Pfizer INC. | $387.37 | 2022-2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $307.33 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $290.35 | 2021-2024 | Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $170.24 | 2022-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $168.47 | 2023-2024 | |
| Sanofi-Aventis U.S. LLC | $147.53 | 2022-2023 | |
| Janssen Pharmaceuticals, INC | $138.33 | 2022-2024 | Xarelto |
| Amgen INC. | $136.92 | 2022-2024 | Repatha |
| Merck Sharp & Dohme LLC | $121.84 | 2022-2024 | Verquvo |
| Astellas Pharma US INC | $116.37 | 2019-2021 | |
| Novo Nordisk INC | $115.14 | 2024 | Ozempic, Rybelsus, Wegovy |
| Heartflow, INC. | $99.46 | 2022-2024 | Ffrct |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cvrx, INC. | $82.74 | 2023-2024 | Barostim Neo System |
| Angiodynamics, INC. | $51.64 | 2024 | Venacure 1470 Pro |
| Esperion Therapeutics, INC. | $50.01 | 2023-2025 | Nexletol |
| Boston Scientific Corporation | $46.44 | 2023 | Watchman Access System |
| Tactile Systems Technology INC | $21.27 | 2025 | Nimbl, Flexitouch Plus |
| Inspire Medical Systems, INC. | $16.61 | 2024 | Inspire |
| Inari Medical, INC. | $14.92 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Cardiovascular Systems INC. | $13.65 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharan Sharma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.